Companies: 10,795·Total market cap: $144.5T
Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc.

ARDSOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$8915
P/E Ratio
52W High$0.05
52W Low$0.0001
SEC Filings

Aridis Pharmaceuticals, Inc. (ARDS) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001614067 · ARDS · OTC · as of Jun 8, 2026

Filing snapshot

313
Total Filings
SCHEDULE 13G/A
Latest Form
2026-05-15
Most Recent
2018
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001614067 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2023-05-22
Fiscal Year End
May 22, 2023
Accession No.
0001493152-23-018590
Primary Document
form10-k.htm
Source: data.sec.gov · CIK 0001614067 · Accession 0001493152-23-018590

Latest Key Filings

10-QQuarterly Report
Quarterly Report
2023-11-06
8-KCurrent Report
Current Report
2024-06-27Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-08-14
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-02-14
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2024-11-14
View
8-KCurrent Report
Current Report
2024-06-27
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2024-02-14
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2024-02-13
View
8-KCurrent Report
Current Report
2024-01-16
View
DEFA14AProxy Statement (Additional)
Proxy Statement (Additional)
2023-12-18
View
8-KCurrent Report
Current Report
2023-12-18
View
DEFA14AProxy Statement (Additional)
Proxy Statement (Additional)
2023-12-15
View
10-QQuarterly Report
Quarterly Report
2023-11-06
View
8-KCurrent Report
Current Report
2023-11-03
View
Showing 1–15 of 257 filingsForm 4 / 144 hidden· 313 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001614067  |  Exchange: OTC · Healthcare

Aridis Pharmaceuticals, Inc. (OTC: ARDS) has submitted 313 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2018. As a Healthcare sector company with CIK 0001614067, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Aridis Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent Aridis Pharmaceuticals, Inc. 10-K was filed on 2023-05-22 for fiscal year ending 2023. Historical ARDS 10-K annual reports are available from 2014 through 2023.

Investors researching Aridis Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

ARDS SEC Filings · 8 questions

Aridis Pharmaceuticals, Inc. (ARDS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 313 filings and access original documents at no cost. Aridis Pharmaceuticals, Inc.'s CIK is 0001614067.

ARDS SEC filingsAridis Pharmaceuticals, Inc. SEC documentsfind ARDS 10-K